ASCO Maintains Clinical Trials Could Be Hindered Under Medicare 2005 Part B Payments
This article was originally published in The Pink Sheet Daily
Reductions in Medicare payments over 2005 could hamper clinical trial enrollment, former ASCO President Margaret Tempero, MD, said during a Capitol Hill briefing Sept. 8
You may also be interested in...
CMS estimates the total drop in Medicare payment reductions for 2005 at 8%; an ASCO survey of community clinics found a 15% payment reduction. ASCO seeks legislation establishing a floor in total payments through 2006.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
Three FDA risk management final guidances recommend that sponsors collect a wide range of safety data during both the clinical trial and postmarketing periods of drug development. The agency suggests that sponsors hold discussions with FDA before settling on drug study designs or postmarketing activities.